EKF Diagnostics Investor Announcements

EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

Pages:

19

Director / PDMR Shareholding

27^th Jun 2016

Director / PDMR Shareholding

24^th Jun 2016

Director / PDMR Shareholding

22^nd Jun 2016

TR-1 notification of major interest in shares

22^nd Jun 2016

Director/PDMR Shareholding

21^st Jun 2016

Director Dealings

10^th Jun 2016

TR-1 notification of major interest in shares

9^th Jun 2016

Result of placing

2^nd Jun 2016

EKF Diagnostics Holdings plc announces the successful completion of the Placing announced this morning.

2^nd Jun 2016

Proposed placing

2^nd Jun 2016

EKF Diagnostics Holdings plc announces the proposed placing of up to 42,205,707 new ordinary shares of 1 penny each in the Company by way of an accelerated book build (the “Placing”).

Pages:

19

Archive

Mount Sinai investments related
RNS announcements

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

TR-1: Standard form for notification of major holdings

Standard form for notification of major holdings.

Director/PDMR Shareholding

EKF Diagnostics Holdings plc (AIM: EKF) announces that on 24 May 2019, the Company was notified by Adam Reynolds, Non-executive Director, that he has today sold 400,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares").

Acquisition of further interest in Renalytix AI plc

EKF Diagnostics Holdings notes the announcement by Renalytix AI plc, that on 26 April 2019 EKF Diagnostics plc acquired 100,074 ordinary RenalytixAI shares of £0.0025 each.

Posting of Annual Report & Accounts and Notice of AGM

EKF Diagnostics confirms that the Annual Report and Accounts for the year ended 31 December 2018 and the Notice of the Annual General Meeting contained therein are available.

EKF Diagnostics Holdings plc announces its final results for the year ended 31 December 2018.

Product showcase

Copyright © 2022 | Powered by Intergage

Quick links

News and Events

Anemia and Hemoglobin testing

Diabetes and HbA1c testing

Support

Social media

EKF Diagnostics - web 50px

Please note: Not all products are available in all countries. Please check availability.

Privacy | Terms & Conditions | Terms of Sale | UK Modern Slavery Act